COMPOSITIONS FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS

(19)

(11)

EP 1 909 837 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	02.06.2010 Bulletin 2010/22

(45)	Mention of the grant of the patent:
	21.04.2010 Bulletin 2010/16

(21)	Application number: 06764231.4

(22)	Date of filing: 19.07.2006

(51)

International Patent Classification (IPC):

A61K 45/06^(2006.01)
A61K 31/506^(2006.01)

A61K 31/553^(2006.01)

(86)	International application number:
	PCT/EP2006/064431

(87)	International publication number:
	WO 2007/010014 (25.01.2007 Gazette 2007/04)

(54)	COMPOSITIONS FOR TREATMENT OF SYSTEMIC MASTOCYTOSIS ZUSAMMENSETZUNGEN ZUR BEHANDLUNG VON SYSTEMISCHER MASTOCYTOSE COMPOSITIONS POUR LE TRAITEMENT DE MASTOCYTOSE SYSTEMIQUE

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

(30)

Priority:

20.07.2005 US 701098 P

(43)	Date of publication of application:
	16.04.2008 Bulletin 2008/16

(73)	Proprietor: Novartis AG
	4056 Basel (CH)

(72)	Inventor:
	Valent Peter 1097 Vienna (AT)

(74)	Representative: Crawley, Patrick Edward et al
	Novartis AG Geistiges Eigentum Konzern Patent- und Markenabteilung CH Postfach 4002 Basel 4002 Basel (CH)

(56)

References cited: :

WO-A-2005/027971
WO-A-2006/135790

WO-A-2005/049032

KLUIN-NELEMANS HANNEKE C ET AL: "Cladribine therapy for systemic mastocytosis." BLOOD, vol. 102, no. 13, 15 December 2003 (2003-12-15), pages 4270-4276, XP007901879 ISSN: 0006-4971
SHAH NEIL P ET AL: "BMS-354825 IS A SRC/ABL INHIBITOR WITH HIGH NANOMOLAR ACTIVITY AGAINST THE KIT D816V MUTATION, WHICH DRIVES SYSTEMIC MASTOCYTOSIS AND IS IMATINIB-RESISTANT" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 104, no. 11, PART 1, November 2004 (2004-11), page 228A, XP008069869 ISSN: 0006-4971
GLEIXNER K V ET AL: "PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects" BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 107, no. 2, 27 September 2005 (2005-09-27), pages 752-759, XP002399639 ISSN: 0006-4971
PARDANANI ET AL: "Pathogenesis, clinical features, and treatment advances in mastocytosis" BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, BAILLIÈRE TINDALL, vol. 19, no. 3, September 2006 (2006-09), pages 595-615, XP005492734 ISSN: 1521-6926
BARBIE D A ET AL: "Systemic mastocytosis: Current classification and novel therapeutic options" CLINICAL ADVANCES IN HEMATOLOGY AND ONCOLOGY 2006 UNITED STATES, vol. 4, no. 10, 2006, pages 768-775, XP009080859 ISSN: 1543-0790
PÉREZ-PÉREZ MARÍA-JESÚS ET AL: "MITOCHONDRIAL THYMIDINE KINASE INHIBITORS" CURRENT TOPICS IN MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, HILVERSUM, NL, vol. 5, no. 13, 2005, pages 1205-1219, XP009078740 ISSN: 1568-0266
CHALANDON Y ET AL: "Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies" HAEMATOLOGICA 2005 ITALY, vol. 90, no. 7, 2005, pages 949-968, XP002425520 ISSN: 0390-6078 cited in the application

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).